Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Changing illness perceptions and adherence to dual antiplatelet therapy in patients with stable coronary disease.

Fennessy MM, Devon HA, Ryan C, Lopez JJ, Zerwic JJ.

J Cardiovasc Nurs. 2013 Nov-Dec;28(6):573-83. doi: 10.1097/JCN.0b013e31825d6060.

PMID:
22785086
2.

Dual antiplatelet therapy in patients with stable coronary artery disease in modern practice: prevalence, correlates, and impact on prognosis (from the Suivi d'une cohorte de patients COROnariens stables en region NORd-Pas-de-Calais study).

Lemesle G, Lamblin N, Meurice T, Tricot O, Lallemant R, Nugue O, Delomez M, Equine O, Tondeux S, Bauters C.

Am Heart J. 2014 Oct;168(4):479-86. doi: 10.1016/j.ahj.2014.06.012. Epub 2014 Jun 19.

PMID:
25262257
3.

Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.

Resor CD, Nathan A, Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Gabriel Steg P, Hsieh WH, Mauri L; Dual Antiplatelet Therapy Study Investigators.

Circulation. 2016 Oct 4;134(14):989-998. Epub 2016 Aug 30.

PMID:
27576774
4.

Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial.

Dangas GD, Claessen BE, Mehran R, Xu K, Stone GW.

EuroIntervention. 2013 Jan 22;8(9):1033-9. doi: 10.4244/EIJV8I9A159.

5.

Percutaneous coronary intervention vs. optimal medical therapy--the other side of the coin: medication adherence.

Kocas C, Abaci O, Oktay V, Coskun U, Bostan C, Yildiz A, Arat Ozkan A, Gurmen T, Ersanli M.

J Clin Pharm Ther. 2013 Dec;38(6):476-9. doi: 10.1111/jcpt.12091. Epub 2013 Aug 31.

PMID:
23992279
6.

Antiplatelet effect of aspirin in patients with coronary artery disease.

Grove EL.

Dan Med J. 2012 Sep;59(9):B4506. Review.

PMID:
22951204
7.

Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.

Savonitto S, Ambrosini V, Marzocchi A, Tolaro S, Petronio AS, Galassi AR, Bongo AS, Gaglione A, Bolognese L; IDEA Survey Investigators; Italian Society of Invasive Cardiology.

Ital Heart J. 2005 Feb;6(2):106-18.

PMID:
15819503
8.

Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation.

Rinfret S, Rodés-Cabau J, Bagur R, Déry JP, Dorais M, Larose E, Barbeau G, Gleeton O, Nguyen CM, Noël B, Proulx G, Roy L, Taillon I, De Larochellière R, Bertrand OF; EASY-IMPACT Investigators.

Heart. 2013 Apr;99(8):562-9. doi: 10.1136/heartjnl-2012-303004. Epub 2013 Feb 23.

PMID:
23434769
9.

Adherence to antiplatelet therapy after percutaneous coronary intervention: a population study in a region of Italy.

Pinnarelli L, Mayer F, Bauleo L, Agabiti N, Kirchmayer U, Belleudi V, Di Martino M, Autore C, Ricci R, Violini R, Fusco D, Davoli M, Perucci CA.

J Cardiovasc Med (Hagerstown). 2015 Mar;16(3):230-7. doi: 10.2459/JCM.0000000000000070.

PMID:
25325532
11.

Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease.

Larsen SB, Grove EL, Kristensen SD, Hvas AM.

Thromb Haemost. 2013 May;109(5):920-9. doi: 10.1160/TH12-09-0666. Epub 2013 Feb 14.

PMID:
23407706
12.

Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.

Tada T, Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Byrne RA, Kastrati A, Kadota K, Iwabuchi M, Shizuta S, Tazaki J, Shiomi H, Abe M, Ehara N, Mizoguchi T, Mitsuoka H, Inada T, Araki M, Kaburagi S, Taniguchi R, Eizawa H, Nakano A, Suwa S, Takizawa A, Nohara R, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kimura T; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators.

Circ Cardiovasc Interv. 2012 Jun;5(3):381-91. doi: 10.1161/CIRCINTERVENTIONS.111.967463. Epub 2012 May 22.

13.

Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.

Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators.

Circulation. 2009 Jun 30;119(25):3215-22. doi: 10.1161/CIRCULATIONAHA.108.833236. Epub 2009 Jun 15.

14.

Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).

Campo G, Tebaldi M, Vranckx P, Biscaglia S, Tumscitz C, Ferrari R, Valgimigli M.

J Am Coll Cardiol. 2014 Feb 18;63(6):506-12. doi: 10.1016/j.jacc.2013.09.043. Epub 2013 Oct 23.

15.

Non-adherence to aspirin in patients undergoing coronary stenting: negative impact of comorbid conditions and implications for clinical management.

Cuisset T, Quilici J, Fugon L, Cohen W, Roux P, Gaborit B, Molines L, Fourcade L, Bonnet JL, Carrieri P.

Arch Cardiovasc Dis. 2011 May;104(5):306-12. doi: 10.1016/j.acvd.2011.03.091. Epub 2011 May 31.

16.

[Adherence to antiplatelet therapy in patients with coronary artery disease].

Legrand D, Legrand V.

Rev Med Liege. 2010 May-Jun;65(5-6):304-10. French.

17.

Practice patterns and trends in the use of medical therapy in patients undergoing percutaneous coronary intervention in Ontario.

Garg P, Wijeysundera HC, Yun L, Cantor WJ, Ko DT.

J Am Heart Assoc. 2014 Aug 13;3(4). pii: e000882. doi: 10.1161/JAHA.114.000882.

18.

Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.

Reaume KT, Regal RE, Dorsch MP.

Ann Pharmacother. 2008 Apr;42(4):550-7. doi: 10.1345/aph.1K433. Epub 2008 Mar 4. Review.

PMID:
18319394
19.

The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease.

Würtz M, Grove EL, Kristensen SD, Hvas AM.

Heart. 2010 Mar;96(5):368-71. doi: 10.1136/hrt.2009.181107. Epub 2009 Nov 11.

PMID:
19910291
20.

Adherence to dual antiplatelet therapy after coronary stenting: a systematic review.

Czarny MJ, Nathan AS, Yeh RW, Mauri L.

Clin Cardiol. 2014 Aug;37(8):505-13. doi: 10.1002/clc.22289. Epub 2014 May 2. Review.

Supplemental Content

Support Center